Scotch Plains, NJ, United States of America

Jack D Scott

This inventor holds 45 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 33 EPO patents, primarily in BACE Inhibitors. Top assignees: Merck Sharp + Dohme Corp., Schering Corporation, Intervet Inc.. Active years: 1980-2021.

USPTO Granted Patents = 45 

% Patents Active = 80.0

 

 

Average Co-Inventor Count = 4.3

ph-index = 8

Forward Citations = 181(Granted Patents)


Location History:

  • Twin Falls, ID (US) (1980)
  • Springfield, NJ (US) (2007 - 2008)
  • Scotch Plains, NJ (US) (2010 - 2021)

Company Filing History:


Years Active: 1980-2021

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
BACE Inhibitors
Leucine-Rich Repeat Kinase
Metallo-Beta-Lactamase
Iminothiadiazine
Compounds
Thiadiazine
Piperazine Derivatives
Cannabinoid Receptor Modulators
Spirorings
Oxacyclic Compounds
Enzyme Activity
Antagonists
45 patents (USPTO):Explore Patents

Title: The Innovative Journey of Jack D Scott: Pioneering Inventions in Pharmaceutical Sciences

Introduction:

Jack D Scott, a distinguished inventor based in Scotch Plains, NJ, has made significant contributions to the field of pharmaceutical sciences. With an impressive portfolio of 45 patents, his groundbreaking work in developing Metallo-β-lactamase inhibitors and compounds inhibiting leucine-rich repeat kinase enzyme activity has revolutionized the landscape of antibiotic resistance and disease treatment.

Latest Patents:

1. Metallo-β-lactamase Inhibitors and Methods of Use Thereof: Jack D Scott's invention focuses on metallo-β-lactamase inhibitor compounds that are crucial in overcoming antibiotic resistance. This innovative approach not only entails the synthesis of these compounds but also their effective utilization in combination with β-lactam antibiotics and beta-lactamase inhibitors to combat bacterial infections.

2. Compounds Inhibiting Leucine-Rich Repeat Kinase Enzyme Activity: In his latest patent, Jack D Scott introduces substituted reversed indazole compounds as potent inhibitors of LRRK2 kinase. These compounds exhibit immense potential in treating diseases such as Parkinson's Disease, where LRRK2 kinase plays a pivotal role. The patent also encompasses the formulation of pharmaceutical compositions for the prevention and treatment of these diseases.

Career Highlights:

Jack D Scott has honed his expertise through collaborations with renowned pharmaceutical companies such as Merck Sharp & Dohme Corporation and Schering Corporation. His tenure in these esteemed organizations has been marked by relentless innovation and a commitment to translating scientific discoveries into tangible solutions for global healthcare challenges.

Collaborations:

During his professional journey, Jack D Scott has had the privilege of working alongside esteemed colleagues like Jared N Cumming and Andrew William Stamford. These collaborative efforts have played a crucial role in advancing the frontiers of pharmaceutical research and development, paving the way for novel therapeutic interventions.

Conclusion:

In conclusion, Jack D Scott stands as a beacon of ingenuity in the realms of pharmaceutical inventions. His unwavering dedication to addressing antibiotic resistance and neurodegenerative diseases through pioneering patents underscores his profound impact on the healthcare landscape. With an illustrious career marked by innovation and collaboration, Jack D Scott continues to inspire future generations of inventors in the pursuit of transformative scientific breakthroughs.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…